Accelerating Regeneration
We are changing the standard of care for treating peripheral nerve injuries.
RECENT NEWS
Epineuron selected as a pitch finalist at the MaRS Healthkick Invest conference, the largest early-stage health investment conference in Canada. Come support us!
March 30, 2019
Epineuron wins grand prize at the 6th annual Synapse Life Science Competition.
March 27, 2019
Epineuron co-founders Sergio Aguirre and Dr. Mike Willand have been featured on the ZoneCast Podcast.
March 4, 2019
Epineuron has been selected by the Ontario Brain Institute to present at the 2019 OBIO Niagara Investment Summit
January 15, 2019
Epineuron has been selected as a finalist for the 2019 Synapse Life Science Competition.
December 11th, 2018
The FDA has granted Epineuron a Breakthrough Device Designation for it's novel Temporary Peripheral Nerve Stimulation (TPNS) System.
June 1st, 2018
Outside of surgery, there are no treatments for injured nerves.
Peripheral nerve injury can result from a nerve transection, crush, compression, traction, and ischemia. Any of these injuries can cause physical disability that impacts the quality of life and ability to live and function normally.
17.5 MILLION
nerve procedures per year performed globally
>1 MILLION
nerve procedures per year in North America
Our Mission
We are building the world’s first electroceutical device engineered to supercharge the nerve and accelerate regeneration. Our technology delivers electrical stimulation that boosts the nerve’s natural biochemical process to heal and repair itself when injured.
